Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice TargetHot
Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.
Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.